Redefining multidrug-resistant tuberculosis based on clinical response to combination therapy

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 10, 2014, Pages 6111-6115

  Gumbo, Tawanda ^a   Pasipanodya, Jotam G ^a   Wash, Peter ^b   Burger, André ^b   McIlleron, Helen ^c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b Brewelskloof Hospital   (South Africa)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL DECISION MAKING; COHORT ANALYSIS; DIRECTLY OBSERVED THERAPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; OUTCOME ASSESSMENT; SOUTH AFRICA; SPUTUM CULTURE; SPUTUM CYTODIAGNOSIS; TREATMENT FAILURE; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; MULTIDRUG RESISTANCE; PROSPECTIVE STUDY; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

ADULT; AGED; ANTITUBERCULAR AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; ISONIAZID; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PROSPECTIVE STUDIES; RIFAMPIN; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 84907266364     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03549-14     Document Type: Article

References (40)

1. Migliori GB, Sotgiu G, Gandhi NR, Falzon D, DeRiemer K, Centis R, Hollm-Delgado MG, Palmero D, Pérez-Guzmän C, Vargas MH, D'Ambrosio L, Spanevello A, Bauer M, Chan ED, Schaaf HS, Keshavjee S, Holtz TH, Menzies D, Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB. 2013. Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data metaanalysis. Eur. Respir. J. 42:169-179. http://dx.doi.org/10.1183/09031936 .00136312.
2. Centers for Disease Control and Prevention (CDC). 2006. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs-worldwide, 2000-2004.MMWRMorb. Mortal. Wkly. Rep. 55:301-305.
3. World Health Organization. 2010. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. World Health Organization, Geneva, Switzerland. http://whqlibdoc.who.int/public ations/2010/9789241599191-eng.pdf?ua-1.
4. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, Zeller K, Andrews J, Friedland G. 2006. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 368:1575-1580. http://dx.doi .org/10.1016/S0140-6736(06)69573-1.
5. Dheda K, Gumbo T, Gandhi NR, Murray M, Theron G, Udwadia Z, Migliori GB, Warren R. 2014. Global control of tuberculosis: from extensively- drug resistant to untreatable tuberculosis. Lancet Respir. Med. 2:321-338. http://dx.doi.org/10.1016/S2213-2600(14)70031-1.
6. Canetti G, Froman S, Grosset J, Hauduroy P, Langerova M, Mahler HT, Meissner G, Mitchison DA, Sula L. 1963. Mycobacteria: laboratory methods for testing drug sensitivity and resistance. Bull. World Health Organ. 29:565-578.
7. Ambrose PG. 2006. Monte Carlo simulation in the evaluation of susceptibility breakpoints: predicting the future: insights from the society of infectious diseases pharmacists. Pharmacotherapy 26:129-134. http://dx .doi.org/10.1592/phco.2006.26.1.129.
8. Clinical and Laboratory Standards Institute. 2003. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; approved standard. Clinical and Laboratory Standards Institute, Wayne, PA.
9. Drusano GL, Preston SL, Hardalo C, Hare R, Banfield C, Andes D, Vesga O, Craig WA. 2001. Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint. Antimicrob. Agents Chemother. 45:13-22. http://dx.doi.org/10 .1128/AAC.45.1.13-22.2001.
10. Gumbo T, Louie A, Deziel MR, Liu W, Parsons LM, Salfinger M, Drusano GL. 2007. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob. Agents Chemother. 51:3781-3788. http://dx.doi.org/10.1128/AAC.01533-06.
11. Gumbo T, Louie A, Liu W, Brown D, Ambrose PG, Bhavnani SM, Drusano GL. 2007. Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations. Antimicrob. Agents Chemother. 51:2329-2336. http://dx.doi.org/10.1128/AAC.00185-07.
12. Gumbo T, Siyambalapitiyage Dona CS, Meek C, Leff R. 2009. Pharmacokinetics- pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs. Antimicrob. Agents Chemother. 53:3197-3204. http://dx.doi.org/10.1128/AAC.01681-08.
13. Srivastava S, Musuka S, Sherman C, Meek C, Leff R, Gumbo T. 2010. Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol. J. Infect. Dis. 201:1225-1231. http://dx.doi.org/10.1086/651377.
14. Chigutsa E, Pasipanodya JG, Sirgel FA, Gumbo T, McIlleron H. 2013. Multivariate adaptive regression splines analysis of the effect of drug concentration and MIC on sterilizing activity in patients on multidrug therapy, abstr. 14, p 15. Abstr. 6th Int. Workshop Clin. Pharmacol. Tuberc. Drugs, Denver, CO.
15. Pasipanodya JG, McIlleron H, Burger A, Wash PA, Smith P, Gumbo T. 2013. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J. Infect. Dis. 208:1464-1473. http://dx.doi.org/10.1093/infdis /jit352.
16. Pasipanodya JG, Srivastava S, Gumbo T. 2012. Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy. Clin. Infect. Dis. 55:169-177. http://dx.doi.org/10.1093/cid/cis353.
17. Gumbo T. 2010. New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability. Antimicrob. Agents Chemother. 54:1484-1491. http://dx.doi.org/10.1128/AAC.01474-09.
18. McIlleron H, Wash P, Burger A, Norman J, Folb PI, Smith P. 2006. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob. Agents Chemother. 50:1170-1177. http://dx.doi.org/10.1128/AAC.50 .4.1170-1177.2006.
19. Breiman L, Friedman J, Stone CJ, Olshen RA. 1984. Classification and regression trees. Chapman & Hall/CRC, Boca Raton, FL.
20. Kim H, Loh W-Y. 2001. Classification trees with unbiased multiway splits. J. Am. Stat. Assoc. 88:457-467. http://dx.doi.org/10.1198/0162145 01753168271.
21. Steinberg D, Colla P. 1995. CART: tree-structured non-parametric data analysis. Salford Systems, San Diego, CA.
22. Lewis RJ. 2000. An introduction to classification and regression tree (CART) analysis. Annu. Meet. Soc. Acad. Emerg. Med. 2000. Society for Academic Emergency Medicine, Des Plaines, IL. http://www.freewebs .com/achi/lewis1.pdf.
23. Andes D, Ambrose PG, Hammel JP, Van Wart SA, Iyer V, Reynolds DK, Buell DN, Kovanda LL, Bhavnani SM. 2011. Use of pharmacokinetic- pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia. Antimicrob. Agents Chemother. 55:2113-2121. http://dx.doi.org/10.1128/AAC .01430-10.
24. Jain MK, Pasipanodya JG, Alder L, Lee WM, Gumbo T. 2013. Pegylated interferon fractal pharmacokinetics: individualized dosing for hepatitis C virus infection. Antimicrob. Agents Chemother. 57:1115-1120. http://dx .doi.org/10.1128/AAC.02208-12.
25. Gumbo T, Chigutsa E, Pasipanodya JG, Visser M, McIlleron H, Sirgel FA. 2014. The pyrazinamide susceptibility breakpoint above which combination therapy fails. J. Antimicrob. Chemother. 69:2420-2425. http://dx.doi.org/10.1093/jac/dkt524.
26. Drusano GL, Johnson DE, Rosen M, Standiford HC. 1993. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob. Agents Chemother. 37:483-490. http://dx.doi.org/10.1128/AAC.37.3.483.
27. Craig WA. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-10. http://dx.doi.org/10.1086/516284.
28. Craig WA. 2007. Pharmacodynamics of antimicrobials: general concepts and applications, p 1-19. In Nightangle CH, Ambrose PG, Drusano GL, Murakawa T (ed), Antimicrobial pharmacodynamics in theory and practice, 2nd ed, vol. 44. Informa Healthcare USA, Inc., New York, NY.
29. Ambrose PG, Bhavnani SM, Rubino CM, Louie A, Gumbo T, Forrest A, Drusano GL. 2007. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin. Infect. Dis. 44:79-86. http://dx.doi.org/10.1086/510079.
30. Williamson DA, Roberts SA, Bower JE, Vaughan R, Newton S, Lowe O, Lewis CA, Freeman JT. 2012. Clinical failures associated with rpoB mutations in phenotypically occult multidrug-resistant Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 16:216-220. http://dx.doi.org/10 .5588/ijtld.11.0178.
31. van Ingen J, Aarnoutse R, de Vries G, Boeree MJ, van Soolingen D. 2011. Low-level rifampicin-resistant Mycobacterium tuberculosis strains raise a new therapeutic challenge. Int. J. Tuberc. Lung Dis. 15:990-992. http://dx.doi.org/10.5588/ijtld.10.0127.
32. Ho J, Jelfs P, Sintchencko V. 2013. Phenotypically occult multidrugresistant Mycobacterium tuberculosis: dilemmas in diagnosis and treatment. J. Antimicrob. Chemother. 68:2915-2920. http://dx.doi.org/10 .1093/jac/dkt284.
33. Pasipanodya JG, Gumbo T. 2011. A new evolutionary and pharmacokinetic- pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugs. Curr. Opin. Pharmacol. 11:457-463. http://dx.doi.org/10.1016/j.coph.2011.07.001.
34. Schmalstieg AM, Srivastava S, Belkaya S, Deshpande D, Meek C, Leff R, van Oers NS, Gumbo T. 2012. The antibiotic resistance arrow of time: efflux pump induction is a general first step in the evolution of mycobacterial drug resistance. Antimicrob. Agents Chemother. 56:4806-4815. http://dx.doi.org/10.1128/AAC.05546-11.
35. Zimic M, Fuentes P, Gilman RH, Gutierrez AH, Kirwan D, Sheen P. 2012. Pyrazinoic acid efflux rate in Mycobacterium tuberculosis is a better proxy of pyrazinamide resistance. Tuberculosis (Edinb.) 92:84-91. http://dx.doi.org/10.1016/j.tube.2011.09.002.
36. Louw GE, Warren RM, Gey van Pittius NC, Leon R, Jimenez A, Pando RH, McEvoy CR, Grobbelaar M, Murray M, van Helden PD, Victor TC. 2011. Rifampicin reduces susceptibility to ofloxacin in rifampicin resistant Mycobacterium tuberculosis through efflux. Am. J. Respir. Crit. Care Med. 184:269-276.
37. Gumbo T, Louie A, Liu W, Ambrose PG, Bhavnani SM, Brown D, Drusano GL. 2007. Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth. J. Infect. Dis. 195:194-201. http://dx.doi.org/10 .1086/510247.
38. Machado D, Couto I, Perdigao J, Rodrigues L, Portugal I, Baptista P, Veigas B, Amaral L, Viveiros M. 2012. Contribution of efflux to the emergence of isoniazid and multidrug resistance in Mycobacterium tuberculosis. PLoS One 7(4):e34538. http://dx.doi.org/10.1371/journal.pone .0034538.
39. Gumbo T, Hiemenz J, Ma L, Keirns JJ, Buell DN, Drusano GL. 2008. Population pharmacokinetics of micafungin in adult patients. Diagn. Microbiol. Infect. Dis. 60:329-331. http://dx.doi.org/10.1016/j.diagmicrobio.2007. 09.018.
40. Pasipanodya JG, Srivastava S, Gumbo T. 2012. Scientific and patient care evidence to change susceptibility breakpoints for first-line antituberculosis drugs. Int. J. Tuberc. Lung Dis. 16:706-707. http://dx.doi.org /10.5588/ijtld.11.0850.